FIELD: biotechnology.
SUBSTANCE: disclosed is an anti-LILRB1 antibody or an antigen-binding fragment thereof. Also disclosed are pharmaceutical compositions containing said antibodies for inhibiting immune evasion of tumor cells and treating oncological disease. Invention also relates to a nucleic acid coding an anti-LILRB1 antibody, a recombinant expression vector and a recombinant cell containing said nucleic acid, a method of producing an anti-LILRB1 antibody.
EFFECT: invention provides antibodies against LILRB1, having high specificity in relation to LILRB1.
12 cl, 5 dwg, 22 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| ANTI-HUMAN ANGIOPOIETIN-LIKE 4 PROTEIN ANTIBODIES | 2010 |
|
RU2580045C2 |
| ANTIBODY FOR SPECIFIC BINDING TO N-TERMINAL DOMAIN OF LYSYL-TRNA SYNTHETASE EXPOSED ON EXTRACELLULAR MEMBRANE | 2019 |
|
RU2781304C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
| ANTIBODY SPECIFICALLY BINDING TO ICAM-1 AND ITS USE | 2019 |
|
RU2789757C2 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| NEW O-SUCCINYL HOMOSERINE TRANSFERASE VARIANT AND METHOD FOR SYNTHESIS OF O-SUCCINYL HOMOSERINE USING SAID VARIANT | 2018 |
|
RU2747493C1 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
